Search Results - "Cutler, NR"

Recent developments in the drug treatment of Alzheimer's disease by SRAMEK, J. J, CUTLER, N. R

“…Alzheimer's disease (AD) is a chronic neurodegenerative disorder with an impact on public health which continues to increase with the increasing longevity of…”
Get full text

Penetration of trovafloxacin into cerebrospinal fluid in humans following intravenous infusion of alatrofloxacin by CUTLER, N. R, VINCENT, J, JHEE, S. S, TENG, R, WARDLE, T, LUCAS, G, DOGOLO, L. C, SRAMEK, J. J

“…Services AAC Citing Articles Google Scholar PubMed Related Content Social Bookmarking CiteULike Delicious Digg Facebook Google+ Mendeley Reddit StumbleUpon…”
Get full text

Pilot study of MK-462 in migraine by Cutler, N R, Claghorn, J, Sramek, J J, Block, G, Panebianco, D, Cheng, H, Olah, T V, Reines, S A

“…MK-462 is a potent, selective 5HT1D receptor agonist which may be useful in treating acute migraine. We conducted a double-blind placebo-controlled inpatient…”
Get more information

A randomized evaluation of the effects of six antipsychotic agents on QTc, in the absence and presence of metabolic inhibition by HARRIGAN, Edmund P, MICELI, Jeffrey J, ANZIANO, Richard, WATSKY, Eric, REEVES, Karen R, CUTLER, Neal R, SRAMEK, T. John, SHIOVITZ, Thomas, MIDDLE, Michelle

“…Many drugs have been associated with QTc prolongation and, in some cases, this is augmented by concomitant administration with metabolic inhibitors. The…”
Get full text

Inhibition of acetyl- and butyryl-cholinesterase in the cerebrospinal fluid of patients with Alzheimer's disease by rivastigmine: correlation with cognitive benefit by GIACOBINI, E, SPIEGEL, R, ENZ, A, VEROFF, A. E, CUTLER, N. R

“…Cholinesterase (ChE) inhibition represents the most efficacious treatment approach for Alzheimer's disease (AD) to date. This multiple-dose study has examined…”
Get full text

Pharmacokinetics and Pharmacodynamics of Avitriptan in Patients With Migraine After Oral Dosing by Cutler, Neal R., Salazar, Daniel E., Jhee, Stanford S., Fulmor, I. Edgar, Ford, Neville, Smith, Robert A., Sramek, John J.

“…Avitriptan (BMS‐180048) is a 5‐HT1‐like receptor agonist for the treatment of migraine. This double‐blind, placebo‐controlled, randomized, parallel‐group study…”
Get full text

Galantamine hydrobromide: an agent for Alzheimer's disease by Zarotsky, Victoria, Sramek, John J, Cutler, Neal R

“…The pharmacology, dosage, adverse effects, efficacy, and economics of galantamine hydrobromide are discussed. Galantamine hydrobromide is a tertiary alkaloid…”
Get full text

Balancing risk and benefit in venous thromboembolism trials: concept for a bivariate endpoint trial design and analytic approach by Kittelson, J. M., Spyropoulos, A. C., Halperin, J. L., Kessler, C. M., Schulman, S., Steg, G., Turpie, A. G. G., Cutler, N. R., Hiatt, W. R., Goldenberg, N. A.

“…Summary Antithrombotic trials in venous thromboembolism treatment and prevention, including those evaluating the new oral anticoagulants, have typically…”
Get full text

Sertraline in Children and Adolescents With Obsessive-Compulsive Disorder: A Multicenter Randomized Controlled Trial by March, John S, Biederman, Joseph, Wolkow, Robert, Safferman, Allan, Mardekian, Jack, Cook, Edwin H, Cutler, Neal R, Dominguez, Roberto, Ferguson, James, Muller, Betty, Riesenberg, Robert, Rosenthal, Murray, Sallee, Floyd R, Wagner, Karen D

“…CONTEXT.— The serotonin reuptake inhibitors are the treatment of choice for patients with obsessive-compulsive disorder; however, empirical support for this…”
Get full text

Generalised anxiety disorder: Treatment options by SRAMEK, John J, ZAROTSKY, Victoria, CUTLER, Neal R

“…In recent years generalised anxiety disorder (GAD) has become a much better defined disorder, with specific criteria distinguishing it from the other anxiety…”
Get full text

Review of the acetylcholinesterase inhibitor galanthamine by Sramek, J J, Frackiewicz, E J, Cutler, N R

“…Galanthamine (or galantamine, Reminyl) is a tertiary alkaloid acetylcholinesterase inhibitor (AChEI) which has been approved in several countries for the…”
Get more information

Pharmacokinetics and pharmacodynamics of the triptan antimigraine agents: A comparative review by JHEE, Stanford S, SHIOVITZ, Thomas, CRAWFORD, Aaron W, CUTLER, Neal R

“…The current approach to antimigraine therapy comprises potent serotonin 5-HT1B/1D receptor agonists collectively termed triptans. Sumatriptan was the first of…”
Get full text

Cholinesterase inhibitors: a therapeutic strategy for Alzheimer disease by Krall, WJ, Sramek, JJ, Cutler, NR

“…OBJECTIVE: To provide a review of acetylcholinesterase inhibitors (AChEIs) tested as therapeutic agents for Alzheimer disease (AD). DATA SOURCES: MEDLINE…”
Get full text

Life course of illness in untreated manic-depressive patients by Cutler, N R, Post, R M

Get more information

Review of the next generation of Alzheimer's disease therapeutics: challenges for drug development by Cutler, Neal R., Sramek, John J.

“…1. AD is believed to stem from dysfunctional cholinergic signaling in the regions of the brain associated with memory and cognition. 2. The occurrence of AD in…”
Get full text

Pharmacokinetic studies of antipsychotics in healthy volunteers versus patients by Cutler, N R

“…In clinical trials of dopamine-blocking antipsychotics, significant adverse events may occur in healthy volunteers at dose levels that are well tolerated by…”
Get full text

Safety and efficacy of PNU-142633, a selective 5-HT1D agonist, in patients with acute migraine by Gomez-Mancilla, B, Cutler, N R, Leibowitz, M T, Spierings, E L, Klapper, J A, Diamond, S, Goldstein, J, Smith, T, Couch, J R, Fleishaker, J, Azie, N, Blunt, D E

“…In this randomized, double-blind, placebo-controlled, parallel-group study, patients received a single 50-mg oral dose of a 5-HT(1D) agonist, PNU-142633 (n =…”
Get more information

Gender differences in depression and antidepressant pharmacokinetics and adverse events by Frackiewicz, EJ, Sramek, JJ, Cutler, NR

“…OBJECTIVE: To review data generated by studies examining gender differences in the prevalence of depression, as well as in antidepressant pharmacokinetics,…”
Get full text

Galantamine hydrobromide: an agent for Alzheimer's disease by Zarotsky, V, Sramek, JJ, Cutler, NR

Get full text

Estimation of the absolute bioavailability of rivastigmine in patients with mild to moderate dementia of the Alzheimer's type by HOSSAIN, Mohammad, JHEE, Stanford S, SHIOVITZ, Thomas, MCDONALD, Craig, SEDEK, Greg, POMMIER, Francoise, CUTLER, Neal R

“…To investigate the bioavailability of rivastigmine, an approved therapy for patients with mild to moderate dementia of the Alzheimer's type, at the highest…”
Get full text